HRT Financial LP Sells Shares of Clearmind Medicine

On June 12, 2026, HRT Financial LP sold 2,102 shares of Clearmind Medicine Inc. (NasdaqCM: CMND) at an average price of $3.36 each, amounting to $7,062.72. This transaction was not part of a pre-planned trading program.

What Changed in HRT Financial LP's Clearmind Medicine Position

HRT Financial LP made a move to sell 2,102 shares of Clearmind Medicine on June 12, 2026. The sale was executed at an average price of $3.36 per share, totaling $7,062.72. This indicates a strategic decision to reduce their holdings in the company.

Other Institutional Activity in Clearmind Medicine

Several other institutional investors also adjusted their positions in Clearmind Medicine. XTX TOPCO LTD increased its holdings significantly by adding 21,694 shares, bringing its total to 21,694 shares valued at approximately $22,562. AdvisorShares Investments LLC grew its position by 725 shares, ending with 7,357 shares worth about $7,651. Meanwhile, JPMorgan Chase & Co completely exited its position, selling off its remaining 5 shares.

Clearmind Medicine Stock Snapshot

Shares of Clearmind Medicine (NasdaqCM: CMND) traded near $3.27. The company has a market capitalization of about $3.43 million and exhibits a beta of -1.242, indicating it moves inversely to the market. The stock's 52-week range spans from a low of $2.10 to a high of $524.00, with a 50-day moving average of $6.08 and a 200-day moving average of $117.80. Clearmind maintains a current ratio of 3.794 and a quick ratio of 3.712, with a low debt-to-equity ratio of 0.097.

Insider Buying and Selling at Clearmind Medicine Inc.

Apart from the recent sale, HRT Financial LP was active in trading Clearmind Medicine shares. On June 11, 2026, they sold 225,191 shares at $0.12 each. Earlier, on June 10, 2026, they purchased 2,159,052 shares at $0.15 per share. These transactions were not part of a pre-planned trading program.

About Clearmind Medicine

Clearmind Medicine Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada. It focuses on developing psychedelic medicines to address under-served health issues such as alcohol use disorders, binge drinking, eating disorders, and anxiety. The company is led by CEO Dr. Adi Zuloff-Shani and is actively involved in several strategic collaborations to advance its research and development efforts.

Bottom Line

HRT Financial LP's recent sale of Clearmind Medicine shares highlights ongoing changes in institutional interest. Investors keep a close eye on such transactions to gauge sentiment and strategic shifts. Remember, these insider activities are reported after the fact and may not reflect current positions.